India’s Sun Pharma Aims To Buy Controlling Stake In Israel’s Taro Under Merger Pact Options Clause
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's Sun Pharma said it will exercise an option to buy 12 percent of Israel-based Taro Pharma held by the founding Levitt family, which includes special voting shares that would give the Mumbai-based firm control to end a disputed merger agreement
You may also be interested in...
PharmAsia News Notable Notes: Citigroup Reiterates Buy On India’s Sun Pharma
NEW DELHI - Citigroup Global Markets reiterated its buy on Sun Pharma, India's largest drug company by market capitalization, saying a recent price dip related to a disputed merger attempt with Israel's Taro Pharma offers a "window of opportunity.
PharmAsia News Notable Notes: Citigroup Reiterates Buy On India’s Sun Pharma
NEW DELHI - Citigroup Global Markets reiterated its buy on Sun Pharma, India's largest drug company by market capitalization, saying a recent price dip related to a disputed merger attempt with Israel's Taro Pharma offers a "window of opportunity.
India’s Sun Pharma Claims Taro’s Proposed Sale Of Irish Plant Not Transparent
NEW DELHI - The spurned suitor of Taro Pharma has accused the Israel-based firm of favoring family in the proposed sale of an Irish manufacturing plant at Roscrea, Ireland, in an increasingly bitter battle following Taro's termination of a merger agreement earlier this month